Literature DB >> 33442790

Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome.

Anna Krentowska1, Agnieszka Łebkowska2, Małgorzata Jacewicz-Święcka3, Justyna Hryniewicka3, Monika Leśniewska4, Agnieszka Adamska3, Irina Kowalska2.   

Abstract

PURPOSE: Insulin resistance is an important factor in the pathogenesis of polycystic ovary syndrome (PCOS), which is associated with higher risk of metabolic syndrome (MetS) and cardiovascular complications. Early atherosclerotic lesions may be diagnosed by ultrasonographic parameters: brachial artery flow-mediated dilation after reactive hyperaemia (FMD) and intima-media thickness of common carotid artery (IMT). The aim of the study was to assess the relation of IMT and FMD with clinical and laboratory parameters reflecting metabolic status in young women with different PCOS phenotypes.
METHODS: The study included 154 PCOS patients diagnosed with the Rotterdam criteria, divided into four phenotypes, and 113 healthy women. Laboratory analyses, transvaginal ultrasound, and IMT and FMD measurements were conducted. MetS was diagnosed with International Diabetes Federation/American Heart Association (IDF/AHA) consensus criteria.
RESULTS: MetS was more prevalent in PCOS patients than healthy women (14.29 vs. 5.31%; p = 0.019), with highest prevalence in phenotypes I and II (p = 0.039). IMT and FMD did not differ between PCOS patients and the controls, nor between the PCOS phenotypes. PCOS patients with MetS presented lower FMD than other PCOS patients (p = 0.018). In women with PCOS, FMD correlated with glucose and insulin concentrations in the fasting state (R = -0.33, p = 0.002; R = -0.23, p = 0.026) and at 2 h of OGTT (R = -0.29, p = 0.006; R = -0.26, p = 0.014). In patients with phenotype I, correlations were found between IMT and BMI (R = 0.45, p = 0.006) and between FMD and fasting glucose concentrations (R = -0.46, p = 0.011).
CONCLUSIONS: Metabolic disturbances and the diagnosis of MetS in patients with PCOS, especially in hyperandrogenic phenotypes, might be associated with alterations in IMT and FMD.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular disease; Metabolic syndrome; Polycystic ovary syndrome; Vascular stiffness

Mesh:

Year:  2021        PMID: 33442790     DOI: 10.1007/s12020-020-02596-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  46 in total

Review 1.  Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis.

Authors:  Rouyanne T Ras; Martinette T Streppel; Richard Draijer; Peter L Zock
Journal:  Int J Cardiol       Date:  2012-10-04       Impact factor: 4.164

Review 2.  Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis.

Authors:  Stijn C H van den Oord; Eric J G Sijbrands; Gerrit L ten Kate; David van Klaveren; Ron T van Domburg; Antonius F W van der Steen; Arend F L Schinkel
Journal:  Atherosclerosis       Date:  2013-01-25       Impact factor: 5.162

Review 3.  Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Michelle L Meyer; Angela M Malek; Robert A Wild; Mary T Korytkowski; Evelyn O Talbott
Journal:  Hum Reprod Update       Date:  2011-11-22       Impact factor: 15.610

Review 4.  Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.

Authors:  Robert A Wild; Enrico Carmina; Evanthia Diamanti-Kandarakis; Anuja Dokras; Hector F Escobar-Morreale; Walter Futterweit; Rogerio Lobo; Robert J Norman; Evelyn Talbott; Daniel A Dumesic
Journal:  J Clin Endocrinol Metab       Date:  2010-04-07       Impact factor: 5.958

5.  The prevalence of Type 2 diabetes is not increased in normal-weight women with PCOS.

Authors:  Rasa Pelanis; Jan Roar Mellembakken; Inger Sundström-Poromaa; Pernille Ravn; Laure Morin-Papunen; Juha S Tapanainen; Terhi Piltonen; Johanna Puurunen; Angelica Lindén Hirschberg; Peter Fedorcsak; Marianne Andersen; Dorte Glintborg
Journal:  Hum Reprod       Date:  2017-11-01       Impact factor: 6.918

6.  Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Shiqin Zhu; Bingqian Zhang; Xiao Jiang; Zeyan Li; Shigang Zhao; Linlin Cui; Zi-Jiang Chen
Journal:  Fertil Steril       Date:  2019-01       Impact factor: 7.329

Review 7.  Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.

Authors:  Héctor F Escobar-Morreale
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

8.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

9.  Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression.

Authors:  S S Lim; N S Kakoly; J W J Tan; G Fitzgerald; M Bahri Khomami; A E Joham; S D Cooray; M L Misso; R J Norman; C L Harrison; S Ranasinha; H J Teede; L J Moran
Journal:  Obes Rev       Date:  2018-10-19       Impact factor: 9.213

10.  Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.

Authors:  Dorte Glintborg; Katrine Hass Rubin; Mads Nybo; Bo Abrahamsen; Marianne Andersen
Journal:  Cardiovasc Diabetol       Date:  2018-03-08       Impact factor: 9.951

View more
  5 in total

Review 1.  The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.

Authors:  J J Ge; D J Wang; W Song; S M Shen; W H Ge
Journal:  J Endocrinol Invest       Date:  2021-08-29       Impact factor: 4.256

2.  Transcriptome Profiling of Oocytes at the Germinal Vesicle Stage from Women from Mongolia with Polycystic Ovary Syndrome.

Authors:  Chen Du; Xiujuan Chen
Journal:  Int J Gen Med       Date:  2021-08-12

3.  Assessment of metabolic syndrome in infertile women with polycystic ovary syndrome in a rural population of South India: A cross-sectional study.

Authors:  Sreelalitha Kayali; Thyagaraju Chitra; Sadishkumar Kamalanathan; Hanumanthappa Nandeesha
Journal:  Int J Reprod Biomed       Date:  2022-04-21

Review 4.  Stem Cell Therapies for Human Infertility: Advantages and Challenges.

Authors:  Jin-Xiang Wu; Tian Xia; Li-Ping She; Shu Lin; Xiang-Min Luo
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.064

5.  Hypertension Predisposition and Thermoregulation Delays in Adolescents with Polycystic Ovary Syndrome: A Pilot Study.

Authors:  Styliani Geronikolou; Flora Bacopoulou; Stavros Chryssanthopoulos; Dennis V Cokkinos; George P Chrousos
Journal:  Children (Basel)       Date:  2022-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.